3Degrees Appoints Philippe Vedrenne as Chief Executive Officer, Effective May 1, 2025
3Degrees, a leading global climate solutions provider and certified B Corporation, is pleased to announce the appointment of Philippe Vedrenne as Chief Executive Officer (CEO), effective May 1, 2025. Vedrenne is moving into the role as 3Degrees’ current CEO and co-founder Steve McDougal steps away from leadership of the company. McDougal informed the Board of Directors last year that he would be retiring as CEO; he will maintain his involvement as a member of the Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422978066/en/
3Degrees Appoints Philippe Vedrenne as Chief Executive Officer, Effective May 1, 2025
Vedrenne brings over two decades of global energy market experience operating across multiple continents. Most recently, at Engie, he oversaw trading and retail activities in North and South America for electricity and gas. In this position, he led efforts to bring utility-scale renewable energy solutions to the corporate market by combining wind, solar, and battery asset classes.
Vedrenne began his career in Europe at Gaz de France where he played a foundational role in the creation of Gasely, the trading business unit that evolved into Engie Global Markets, where he later became CEO. While running Engie’s natural gas midstream activities in Europe, he renegotiated the company’s long-term supply contracts to align them with markets, contributed to ensure European security of supply, and helped establish natural gas reverse flows to Ukraine in the wake of the Maidan uprisings and 2014 Russian-Ukrainian war. Before moving to the U.S. in 2021, Vedrenne led two significant projects for Engie: the development of renewable power purchase agreement (PPA) activities in Europe, and the net zero carbon project that defines Engie’s decarbonization ambition and trajectory to carbon neutrality by 2045.
“We are thrilled to welcome Philippe Vedrenne as the next CEO of 3Degrees,” said Dan Kalafatas, 3Degrees’ co-founder and Chair of the Board. “Our global search focused on selecting a new leader with the expertise to drive the next chapters of 3Degrees’ growth. Philippe brings a rare combination of global leadership experience, track record of success, service-leader orientation, and passion for bringing innovative decarbonization solutions to the world. The 3Degrees Board also wants to express deep gratitude to Steve McDougal. In his tenure as CEO, Steve spearheaded the company’s transformation from a small, North American-focused renewable energy commodity company into a leading global climate solutions provider advising some of the largest companies in the world.”
“I could not be more excited to assume the CEO role and help accelerate 3Degrees’ growth and our clients’ climate impact,” said Vedrenne. “The entire team is incredibly strong, with deep market and functional expertise. I’m looking forward to helping fuel the company’s continued expansion in both current and new markets, and to using our unique combination of market participation and client-centric focus to innovate new products and solutions. I’m honored to be asked to join such an exemplary organization, enabling me to work on a challenge of great urgency to us all.”
McDougal added, “Co-founding 3Degrees with Dan Kalafatas, and subsequently leading the company as CEO for the last ten years, has been one of the greatest privileges of my life. I am incredibly proud of what the 3Degrees team has built together over nearly two decades. I look forward to supporting the bright future for 3Degrees in my role on its Board of Directors and feel confident Philippe will be an excellent steward of the company as it expands its impact globally for our clients, partners, suppliers, employees, and the climate.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250422978066/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom